TTAB Says Clinical Trial Label Sufficient Specimen for Registration By Julia Anne Matheson on June 25, 2015 Email this postTweet this postLike this postShare this post on LinkedIn On June 18, 2015, in a non-precedential opinion, the TTAB overturned the USPTO’s refusal of registration of Eli Lilly and Co.’s application for the word mark TRULICITY for diabetes treatment based upon alleged failures in the specimens submitted. Read more
